CSF-1 Expression in First-Passage RI-AML
| Tumor Designation . | Tumor CSF-1 Concentration (pg/mg)* . | Latency (d) . |
|---|---|---|
| 17A-980 | 35.2 | 254 |
| 17B-188 | 36.6 | 206 |
| 17A-I-10 | 40.8 | 205 |
| 17A-954 | 53.6 | 304 |
| 17A-I-8 | 54.0 | 275 |
| 17A-918 | 54.0 | 278 |
| 17B-100 | 55.2 | 238 |
| 17B-69 | 66.2 | 281 |
| 17A-865 | 67.2 | 213 |
| 17B-108 | 76.8 | 310 |
| 17B-149 | 82.2 | 274 |
| 17A-876 | 84.0 | 325 |
| 17B-186 | 109.0 | 299 |
| 17A-I-31 | 178.4 | 454 |
| Tumor Designation . | Tumor CSF-1 Concentration (pg/mg)* . | Latency (d) . |
|---|---|---|
| 17A-980 | 35.2 | 254 |
| 17B-188 | 36.6 | 206 |
| 17A-I-10 | 40.8 | 205 |
| 17A-954 | 53.6 | 304 |
| 17A-I-8 | 54.0 | 275 |
| 17A-918 | 54.0 | 278 |
| 17B-100 | 55.2 | 238 |
| 17B-69 | 66.2 | 281 |
| 17A-865 | 67.2 | 213 |
| 17B-108 | 76.8 | 310 |
| 17B-149 | 82.2 | 274 |
| 17A-876 | 84.0 | 325 |
| 17B-186 | 109.0 | 299 |
| 17A-I-31 | 178.4 | 454 |
There is a direct correlation between RI-AML latency and tumor CSF-1 concentration (r = .8664, P < .0001).
Determined in duplicate by CSF-1 RIA.